Myelodysplastic Syndrome Clinical Trial

Ravulizumab Subcutaneous (SC) Versus Ravulizumab Intravenous (IV) in Adults With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab

Summary

The primary objective of this study is to evaluate pharmacokinetics (PK) of ravulizumab administered subcutaneously via an on-body delivery system (OBDS) compared with intravenously administered ravulizumab in adult participants with PNH who are clinically stable on eculizumab for at least 6 months.

View Full Description

Full Description

The study will consist of up to a 30-day Screening Period, a 10-week Randomized Treatment Period, and an Extension Period of up to 172 weeks.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Male or female ≥18 years of age
Treated with eculizumab for PNH for at least 3 months prior to Day 1
LDH level ≤1.5 × upper limit of normal (ULN) at screening
PNH diagnosis confirmed by documented high-sensitivity flow cytometry.
Documented meningococcal vaccination not more than 3 years prior to, or at the time of, initiating study treatment.
Body weight ≥40 to <100 kilogram (kg)
Female participants of childbearing potential must use highly effective contraception starting at screening and continuing until at least 8 months after the last dose of ravulizumab.
Willing and able to give written informed consent and comply with study visit schedule.

Exclusion Criteria:

More than 1 LDH value > 2 × ULN within the 3 months prior to study entry
History of bone marrow transplantation.
History of or ongoing major cardiac, pulmonary, renal, endocrine, or hepatic disease that, in the opinion of the Investigator or Sponsor, would preclude participation.
Unstable medical conditions (for example, myocardial ischemia, active gastrointestinal bleed, severe congestive heart failure, anticipated need for major surgery within 6 months of randomization, coexisting chronic anemia unrelated to PNH).
Females who are pregnant, breastfeeding or who have a positive pregnancy test at screening or Day 1.
Participation in another interventional clinical study or use of any experimental therapy within 30 days before initiation of study drug on Day 1 in this study or within 5 half-lives of that investigational product, whichever is greater.

Study is for people with:

Myelodysplastic Syndrome

Phase:

Phase 3

Estimated Enrollment:

139

Study ID:

NCT03748823

Recruitment Status:

Completed

Sponsor:

Alexion Pharmaceuticals, Inc.

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 51 Locations for this study

See Locations Near You

Research Site
Los Angeles California, 90089, United States
Research Site
Liverpool , 2170, Australia
Research Site
Parkville , 3050, Australia
Research Site
Vienna , 1090, Austria
Research Site
Antwerpen , 2020, Belgium
Research Site
Bruxelles , 1200, Belgium
Research Site
Hasselt , 3500, Belgium
Research Site
Leuven , 3000, Belgium
Research Site
Botucatu , 18618, Brazil
Research Site
Ribeirão Preto , 14049, Brazil
Research Site
Rio De De Janeiro , 20211, Brazil
Research Site
Salvador , 40170, Brazil
Research Site
Sao Paulo , 05403, Brazil
Research Site
São Paulo , 01308, Brazil
Research Site
Toronto Ontario, M5G 2, Canada
Research Site
Helsinki , 00029, Finland
Research Site
Amiens , 80054, France
Research Site
Brest , 29609, France
Research Site
Lille , 59037, France
Research Site
Montpellier Cedex 5 , 34090, France
Research Site
Nantes cedex 01 , 44093, France
Research Site
Nice , 6200, France
Research Site
Paris , 75010, France
Research Site
Pessac , F-336, France
Research Site
Pierre Benite Cedex , 69495, France
Research Site
Poitiers , 86021, France
Research Site
Rennes Cedex 9 , 35033, France
Research Site
Strasbourg , 67098, France
Research Site
Tours , 37044, France
Research Site
Catania , 95123, Italy
Research Site
Milano , 20122, Italy
Research Site
Roma , 00168, Italy
Research Site
Rome , 161, Italy
Research Site
Maastricht , 6229 , Netherlands
Research Site
Ekaterinburg , 62010, Russian Federation
Research Site
Moscow , 12516, Russian Federation
Research Site
Moscow , 12528, Russian Federation
Research Site
Saint-Petersburg , 19708, Russian Federation
Research Site
Badalona , 8916, Spain
Research Site
Barcelona , 08036, Spain
Research Site
Donostia , 20014, Spain
Research Site
Las Palmas de Gran Canaria , 35020, Spain
Research Site
Madrid , 28040, Spain
Research Site
Majadahonda , 28222, Spain
Research Site
Sevilla , 41013, Spain
Research Site
Uppsala , 75185, Sweden
Research Site
Adana , 01330, Turkey
Research Site
Istambul , 34899, Turkey
Research Site
İstanbul , 34093, Turkey
Research Site
Istanbul , 34096, Turkey
Research Site
Izmir , 35100, Turkey

How clear is this clinincal trial information?

Study is for people with:

Myelodysplastic Syndrome

Phase:

Phase 3

Estimated Enrollment:

139

Study ID:

NCT03748823

Recruitment Status:

Completed

Sponsor:


Alexion Pharmaceuticals, Inc.

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.